QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights from Biological Samples Investing.com

• QIAcuity digital PCR now offers the ability to simultaneously detect up to 12 targets from a single biological sample, more than doubling the previous capability of up to five targets
  
• No instrument hardware changes are required for the upgraded capability thanks to the new QIAcuity Software (ETR:) 3.1 updating and running the QIAcuity High Multiplex Probe PCR Kit
  
• New QIAcuity digital PCR capabilities help make lab work more productive and economical by saving time, reagent consumption, and use of precious sample materials

VENLO, The Netherlands–( BUSINESS WIRE )–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) System with a more than two-fold increase in the number of targets that can be simultaneously to analyze from one biological sample.

The new capabilities overcome the assay design challenges of currently available quantitative multiplex PCR methods, making QIAcuity digital PCR ideal for applications such as translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.

Through a software upgrade and the launch of the new QIAcuity High Multiplex Probe PCR Kit, users can now analyze up to 12 targets simultaneously compared to the previous version offering up to five targets, using their existing instruments without any hardware changes.

This upgrade provides QIAcuity users with powerful technology that amplifies and detects multiple targets within a single reaction. By combining multiple PCR assays, researchers can now maximize sample utilization while reducing time and reagent consumption, speeding up the process to gain deep biological insights.

Analyzing multiple targets simultaneously from a single biological sample is an important step in making QIAcuity an even better choice for revolutionary dPCR applications, said Nitin Sood, senior vice president and head of the Life Sciences business area at QIAGEN. We are exploring ways to further enhance QIAcuity’s capabilities to help researchers gain a deeper biological understanding of any type of sample in a cost-effective manner without tedious optimization or fear of inaccurate quantification.

Adoption of the QIAcuity digital PCR research instrument is strong, with more than 2,700 cumulative placements at the end of 2024 and citations in more than 550 publications. Key customers include pharmaceutical and biotechnology companies, academic and research organizations and forensic laboratories. In fall 2024, QIAGEN expanded its dPCR portfolio into clinical testing with the launch of QIAcuityDx, which is designed to address clinical user segments and applications and to further strengthen the QIAcuity family.

The QIAcuity High Multiplex Probe PCR Kit contains a ready-to-use master mix optimized for microfluidic use in QIAcuity Nanoplates and allows users to easily perform high-order multiplexing on existing QIAcuity instruments. The kit improves the specificity and efficiency of digital probe-based PCR to provide precise singleplex analysis or up to 12-plex analysis.

As a prerequisite for using the QIAcuity High Multiplex Probe PCR Kit, QIAcuity software 3.1 introduces essential features for high-order multiplexing such as crosstalk compensation that corrects signal overlap between targets. This allows researchers to reliably analyze multiple targets in parallel from a single unsplit sample.

The QIAcuity dPCR catalog and custom assays for copy number variation (CNV) analysis and microbial detection have been redesigned to support up to 12-plex reactions. These tests are available through QIAGEN’s GeneGlobe platform.

The combination of sophisticated software and innovative chemistry makes the QIAcuity dPCR the ultimate solution for high-order multiplexing. It improves workflow by offering higher target capacity and improved data reliability, while QIAcuity remains the highest throughput dPCR system and is highly amenable to automation.

QIAGEN’s QIAcuity digital PCR platform uses nanoplates to disperse a sample into thousands of tiny partitions, then read the reaction in each one simultaneously to quantify even the weakest signals from DNA and RNA. The platform integrates partitioning, thermal cycling and recording into a simplified multiplex workflow, reducing processing time from six hours to just two. Available in single, four and eight panel versions, the platform meets the needs of a wide range of laboratory sizes and throughput requirements.

For more information on QIAcuity’s new multiplexing capabilities, visit: https://www.qiagen.com/applications/digital-pcr/beginners/dpcr-multiplexing

About QIAGEN

QIAGEN NV, a holding company headquartered in the Netherlands, is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples that contain the components of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie them together into seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human healthcare) and life sciences (academia, pharmaceutical research and development and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in more than 35 locations worldwide. Additional information can be found at https://www.qiagen.com.

Forward looking statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934 ., with amendments. To the extent any of the statements contained herein relate to QIAGEN’s products, launch and development timing, marketing and/or regulatory approvals, financial and operating prospects, growth and expansion, collaborations, markets, strategy or operating results, including without limitations of expected adjusted net sales and adjusted diluted earnings results, are forward-looking, and the statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of business results and distributions between classes of customers, commercial development of markets for our products to customers in academic community, pharmacy, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN products (including fluctuations due to general economic conditions, the level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and manufacturing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from those of competitors; market acceptance of QIAGEN’s new products and integration of acquired technologies and operations; government actions, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises and their impact on demand for our products and other aspects of our business or other force majeure events; as well as the possibility that anticipated benefits associated with recent acquisitions or pending acquisitions may not materialize as expected; and other factors discussed under the heading Risk Factors in our most recent Annual Report on Form 20-F. For further information, see the discussions in the reports QIAGEN has filed with or provided to the US Securities and Exchange Commission.

Source: QIAGEN NV

Category: Corporation

See the original version on businesswire.com: https://www.businesswire.com/news/home/20250109845369/en/

QIAGEN:
Investor relations
John Gilardi +49 2103 29 11711
Domenica Martorana +49 2103 29 11244
email: ir@QIAGEN.com

Public relations
Thomas Theuringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
email: pr@QIAGEN.com

Source: QIAGEN NV